title: Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST).
abstract: BACKGROUND
  Hyperphosphatemia is an independent risk factor for all-cause and cardiovascular mortality in hemodialysis (HD) patients. Phosphate control often is unsuccessful using conventional dialysis therapies.
  
  
  METHODS
  Short-term analysis of a secondary outcome of an ongoing randomized controlled trial.
  
  
  METHODS
  493 (84%) consecutive patients from 589 patients included in the Convective Transport Study (CONTRAST) by January 2009 from 26 centers in 3 countries.
  
  
  METHODS
  Online hemodiafiltration (HDF) versus continuation of low-flux HD.
  
  
  RESULTS
  Differences in change from baseline to 6 months in phosphate levels and proportion of patients reaching phosphate treatment targets (phosphate < or = 5.5 mg/dL).
  
  
  METHODS
  Phosphate, use of phosphate-binding agents, and proportion of patients achieving treatment targets at baseline, 3 months, and 6 months.
  
  
  RESULTS
  Phosphate levels decreased from 5.18 +/- 0.10 (SE) mg/dL at baseline to 4.87 +/- 0.10 mg/dL at 6 months in HDF patients (P < 0.001) and were stable in HD patients (5.10 +/- 0.10 mg/dL at baseline and 5.03 +/- 0.10 mg/dL after 6 months; P = 0.5). The difference in change in phosphate levels between HD and HDF patients (B = -0.24; 95% CI, -0.52 to 0.03; P = 0.08) increased after adjustment for phosphate-binder use (B = -0.36; 95% CI, -0.65 to -0.06; P = 0.02). The proportion of patients reaching phosphate treatment targets increased from 64% to 74% in HDF patients and was stable in HD patients (66% and 66%); the difference between groups reached statistical significance (P = 0.04). Nutritional parameters and residual renal function were similar in both treatment groups.
  
  
  CONCLUSIONS
  Only predialysis serum phosphate levels were measured; phosphate clearance could therefore not be calculated.
  
  
  CONCLUSIONS
  HDF may help improve phosphate control. Whether this contributes to improved clinical outcome remains to be established.
authors: Department of Nephrology, University Medical Center Utrecht, Utrecht, The Netherlands.
authors: E Lars
authors: EL
authors: Penne
authors: Neelke C
authors: NC
authors: van der Weerd
authors: Marinus A
authors: MA
authors: van den Dorpel
authors: Muriel P C
authors: MP
authors: Grooteman
authors: Renée
authors: R
authors: Lévesque
authors: Menso J
authors: MJ
authors: Nubé
authors: Michiel L
authors: ML
authors: Bots
authors: Peter J
authors: PJ
authors: Blankestijn
authors: Piet M
authors: PM
authors: ter Wee
mesh_terms: D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate / Q000502:physiology; D017583:Hemodiafiltration / Q000379:methods*; D006801:Humans; D054559:Hyperphosphatemia / Q000097:blood* / Q000209:etiology / Q000628:therapy; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010710:Phosphates